89 related articles for article (PubMed ID: 26721724)
1. Formulation and in vitro efficacy of liposomes containing the Hsp90 inhibitor 6BrCaQ in prostate cancer cells.
Sauvage F; Franzè S; Bruneau A; Alami M; Denis S; Nicolas V; Lesieur S; Legrand FX; Barratt G; Messaoudi S; Vergnaud-Gauduchon J
Int J Pharm; 2016 Feb; 499(1-2):101-109. PubMed ID: 26721724
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of nanoliposomes encapsulating the novobiocin analog 6BrCaQ in a triple-negative breast cancer model in mice.
Sauvage F; Fattal E; Al-Shaer W; Denis S; Brotin E; Denoyelle C; Blanc-Fournier C; Toussaint B; Messaoudi S; Alami M; Barratt G; Vergnaud-Gauduchon J
Cancer Lett; 2018 Sep; 432():103-111. PubMed ID: 29883750
[TBL] [Abstract][Full Text] [Related]
3. Discovery and biological activity of 6BrCaQ as an inhibitor of the Hsp90 protein folding machinery.
Audisio D; Messaoudi S; Cegielkowski L; Peyrat JF; Brion JD; Methy-Gonnot D; Radanyi C; Renoir JM; Alami M
ChemMedChem; 2011 May; 6(5):804-15. PubMed ID: 21374821
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antiproliferative activity of 6BrCaQ-TPP conjugates for targeting the mitochondrial heat shock protein TRAP1.
Mathieu C; Chamayou Q; Hyen Luong TT; Naud D; Mahuteau-Betzer F; Alami M; Fattal E; Messaoudi S; Vergnaud-Gauduchon J
Eur J Med Chem; 2022 Feb; 229():114052. PubMed ID: 34952432
[TBL] [Abstract][Full Text] [Related]
5. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
[TBL] [Abstract][Full Text] [Related]
6. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.
Massey AJ; Williamson DS; Browne H; Murray JB; Dokurno P; Shaw T; Macias AT; Daniels Z; Geoffroy S; Dopson M; Lavan P; Matassova N; Francis GL; Graham CJ; Parsons R; Wang Y; Padfield A; Comer M; Drysdale MJ; Wood M
Cancer Chemother Pharmacol; 2010 Aug; 66(3):535-45. PubMed ID: 20012863
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells.
Matthews SB; Vielhauer GA; Manthe CA; Chaguturu VK; Szabla K; Matts RL; Donnelly AC; Blagg BS; Holzbeierlein JM
Prostate; 2010 Jan; 70(1):27-36. PubMed ID: 19739131
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Cytotoxicity of Folic Acid-Targeted Liposomes Co-Loaded with C6 Ceramide and Doxorubicin: In Vitro Evaluation on HeLa, A2780-ADR, and H69-AR Cells.
Sriraman SK; Pan J; Sarisozen C; Luther E; Torchilin V
Mol Pharm; 2016 Feb; 13(2):428-37. PubMed ID: 26702994
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antiproliferative activity of novobiocin analogues as potential hsp90 inhibitors.
Audisio D; Methy-Gonnot D; Radanyi C; Renoir JM; Denis S; Sauvage F; Vergnaud-Gauduchon J; Brion JD; Messaoudi S; Alami M
Eur J Med Chem; 2014 Aug; 83():498-507. PubMed ID: 24992077
[TBL] [Abstract][Full Text] [Related]
11. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.
Lin Z; Peng R; Li Z; Wang Y; Lu C; Shen Y; Wang J; Shi G
Int J Mol Med; 2015 Aug; 36(2):424-32. PubMed ID: 26059743
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
13. Enhanced cytotoxicity of optimized liposomal genistein via specific induction of apoptosis in breast, ovarian and prostate carcinomas.
Phan V; Walters J; Brownlow B; Elbayoumi T
J Drug Target; 2013 Dec; 21(10):1001-11. PubMed ID: 24151835
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological inhibition of HSP90 and ras activity as a new strategy in the treatment of HNSCC.
Misso G; Giuberti G; Lombardi A; Grimaldi A; Ricciardiello F; Giordano A; Tagliaferri P; Abbruzzese A; Caraglia M
J Cell Physiol; 2013 Jan; 228(1):130-41. PubMed ID: 22566192
[TBL] [Abstract][Full Text] [Related]
15. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
[TBL] [Abstract][Full Text] [Related]
16. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.
Wang F; Chen L; Zhang R; Chen Z; Zhu L
J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829
[TBL] [Abstract][Full Text] [Related]
17. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
[TBL] [Abstract][Full Text] [Related]
18. Ultrasound-targeted microbubble destruction combined with dual targeting of HSP72 and HSC70 inhibits HSP90 function and induces extensive tumor-specific apoptosis.
Wang H; Song Y; Hao D; Bai M; Jin L; Gu J; Su Y; Liu L; Jia C; Du L
Int J Oncol; 2014 Jul; 45(1):157-64. PubMed ID: 24736948
[TBL] [Abstract][Full Text] [Related]
19. Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis.
Yasukochi A; Kawakubo T; Nakamura S; Yamamoto K
Biol Chem; 2010 Aug; 391(8):947-58. PubMed ID: 20482316
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90.
Lee SC; Min HY; Choi H; Kim HS; Kim KC; Park SJ; Seong MA; Seo JH; Park HJ; Suh YG; Kim KW; Hong HS; Kim H; Lee MY; Lee J; Lee HY
Mol Pharmacol; 2015 Aug; 88(2):245-55. PubMed ID: 25976766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
